Key result
Novel p54 CLIA yields ~8-fold higher sensitivity than commercial ELISA for detecting ASFV antibodies.
Why the study?
African swine fever lacks effective vaccines or treatments, making efficient disease control dependent on early detection and diagnosis.
The developed CLIA offers a highly specific and sensitive method for rapid detection of African swine fever virus antibodies.
The outbreak of African swine fever (ASF) has caused significant economic losses to animal husbandry worldwide. Currently, there is no effective vaccine or treatment available to control the disease, and therefore, efficient disease control is dependent on early detection and diagnosis of ASF virus (ASFV). In this study, a chemiluminescent immunoassay (CLIA) was developed using the ASFV protein p54 as a serum diagnostic antigen and an anti-p54 monoclonal antibody. After optimizing the working parameters of the CLIA, the sensitivity of the established CLIA was 1:128, ASFV-specific serum antibody was identified, and there was no cross-reaction with other swine virus antibodies. After testing 49 clinical serum samples, the consistency rate between the CLIA and the World Organization for Animal Health (OIE) recommended commercial kit was 100%. Thus, this CLIA had a high degree of specificity, sensitivity, and reliability, and could be used as a rapid detection method for epidemiological investigations of ASFV infection.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied African swine fever virus (ASFV) infection (n=49). Chemiluminescence immunoassay (CLIA) using ASFV p54 protein vs. Commercial ELISA kit was evaluated on Consistency rate between CLIA and commercial kit. A novel chemiluminescence immunoassay using the ASFV p54 protein demonstrated a 100% consistency rate with a commercial ELISA kit and an 8-fold higher sensitivity for detecting ASFV antibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: